Myriad Genetics reported $-1900000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Accelerate Diagnostics AXDX:US -15279000 1.01M
Agilent A:US $ 466M 3M
Becton, Dickinson and BDX:US $ 1362M 105M
Bio Rad Laboratories BIO:US $ 175.52M 38.34M
Biocept BIOC:US $ -2.3M 0.02M
Bruker BRKR:US $ 125.1M 27.1M
Danaher DHR:US $ 2737M 32M
Exact Sciences EXAS:US $ -129.33M 38.31M
Fluidigm FLDM:US $ -23.4M 15.47M
Hologic HOLX:US $ 700.1M 45.3M
Illumina ILMN:US $ 275M 145M
Johnson & Johnson JNJ:US $ 9309M 1549M
Mettler Toledo International MTD:US 257.33M 71.78M
Myriad Genetics MYGN:US $ -1.9M 34.1M
Nanostring Technologies NSTG:US $ -35.93M 10.1M
Orasure Technologies OSUR:US $ -12.33M 6.18M
Pacific Biosciences Of California PACB:US $ -75.03M 13.24M
Perkinelmer PKI:US $ 408.78M 39.75M
Quest Diagnostics DGX:US $ 631M 72M
Quidel QDEL:US $ 640.48M 241.54M
Repligen RGEN:US $ 72.61M 7.34M
Thermo Fisher Scientific TMO:US $ 3682M 304M
Veracyte VCYT:US $ -8.69M 6.56M
Waters WAT:US $ 228.13M 73.03M